Profile data is unavailable for this security.
About the company
Absci Corporation is a clinical-stage biopharmaceutical company advancing therapeutics with generative design. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. It has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.
- Revenue in USD (TTM)2.82m
- Net income in USD-114.60m
- Incorporated2020
- Employees156.00
- LocationAbsci Corp18105 Se Mill Plain BlvdVANCOUVER 98683United StatesUSA
- Phone+1 (302) 658-7581
- Fax+1 (302) 655-5049
- Websitehttps://www.absci.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bicycle Therapeutics PLC (ADR) | 28.34m | -250.66m | 397.48m | 305.00 | -- | 0.6421 | -- | 14.03 | -3.62 | -3.62 | 0.4094 | 8.92 | 0.0322 | -- | 0.4525 | 92,914.76 | -28.47 | -26.61 | -30.66 | -29.60 | -- | -- | -884.51 | -587.28 | -- | -- | 0.0015 | -- | 30.76 | 20.65 | 6.44 | -- | -4.50 | -- |
| NovaBridge Biosciences | 0.00 | -26.33m | 397.75m | 32.00 | -- | 1.54 | -- | -- | -0.3045 | -0.2827 | 0.00 | 2.25 | 0.00 | -- | -- | 0.00 | -10.32 | -26.21 | -10.92 | -30.19 | -- | -- | -- | -389.26 | -- | -- | 0.00 | -- | -100.00 | -- | 39.56 | -- | -51.41 | -- |
| Niagen Bioscience Inc | 124.71m | 20.43m | 398.23m | 104.00 | 20.54 | 5.62 | 18.78 | 3.19 | 0.243 | 0.243 | 1.48 | 0.8875 | 1.61 | 3.07 | 18.34 | 1,199,125.00 | 26.42 | -23.12 | 35.76 | -35.20 | 63.89 | 60.73 | 16.38 | -15.71 | 3.29 | -- | 0.00003 | -- | 19.18 | 16.56 | 273.15 | -- | -26.37 | -- |
| DiaMedica Therapeutics Inc | 0.00 | -31.93m | 405.16m | 27.00 | -- | 7.85 | -- | -- | -0.7173 | -0.7173 | 0.00 | 0.9913 | 0.00 | -- | -- | 0.00 | -58.27 | -43.91 | -63.85 | -46.83 | -- | -- | -- | -- | -- | -- | 0.0003 | -- | -- | -- | -26.12 | -- | 65.72 | -- |
| Century Therapeutics Inc | 113.34m | -26.48m | 405.53m | 140.00 | -- | 1.11 | -- | 3.58 | -0.3086 | -0.3086 | 1.32 | 2.04 | 0.3579 | -- | -- | 809,550.00 | -8.36 | -33.69 | -8.95 | -36.94 | -- | -- | -23.36 | -3,876.28 | -- | -- | 0.00 | -- | 194.81 | -- | 7.40 | -- | -42.55 | -- |
| Ginkgo Bioworks Holdings Inc | 170.16m | -312.76m | 415.42m | 485.00 | -- | 0.8069 | -- | 2.44 | -5.64 | -5.64 | 3.07 | 8.74 | 0.1363 | -- | 7.29 | 350,835.10 | -25.05 | -66.61 | -27.27 | -72.83 | 72.39 | 66.71 | -183.81 | -395.48 | -- | -- | 0.00 | -- | -25.06 | 17.29 | 42.83 | -- | -33.24 | -- |
| Armata Pharmaceuticals Inc | 5.05m | -46.90m | 415.77m | 60.00 | -- | -- | -- | 82.26 | -1.30 | -1.30 | 0.1396 | -2.64 | 0.0538 | -- | 3.39 | 84,233.34 | -49.96 | -47.36 | -- | -60.79 | -- | -- | -928.00 | -829.99 | -- | -2.12 | 2.88 | -- | 14.24 | -- | 72.60 | -- | 53.02 | -- |
| Upstream Bio Inc | 2.80m | -122.77m | 416.10m | 52.00 | -- | 1.10 | -- | 148.66 | -2.30 | -2.30 | 0.0527 | 7.01 | 0.009 | -- | 4.34 | 53,826.92 | -39.18 | -- | -40.67 | -- | -- | -- | -4,366.77 | -- | -- | -- | 0.00 | -- | -0.4202 | -- | -99.70 | -- | -- | -- |
| Anavex Life Sciences Corp | 0.00 | -39.95m | 419.80m | 34.00 | -- | 3.32 | -- | -- | -0.4649 | -0.4649 | 0.00 | 1.37 | 0.00 | -- | -- | 0.00 | -31.08 | -33.08 | -33.63 | -36.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.85 | -- | -- | -- |
| Absci Corp | 2.82m | -114.60m | 421.04m | 156.00 | -- | 1.99 | -- | 149.57 | -0.903 | -0.903 | 0.022 | 1.40 | 0.0117 | -- | 2.25 | 18,044.87 | -47.73 | -37.10 | -54.08 | -41.33 | -- | -- | -4,071.19 | -1,697.47 | -- | -410.97 | 0.0065 | -- | -20.71 | 17.09 | 6.75 | -- | -18.12 | -- |
| Keros Therapeutics Inc | 246.72m | 64.45m | 423.78m | 82.00 | 9.01 | 0.8033 | 6.43 | 1.72 | 1.54 | 1.54 | 6.07 | 17.32 | 0.3732 | -- | 127.17 | 1,459,870.00 | 9.75 | -36.26 | 10.16 | -38.17 | -- | -- | 26.12 | -2,307.89 | -- | -- | 0.00 | -- | 2,250.99 | -18.71 | -22.46 | -- | 48.10 | -- |
| Lenz Therapeutics Inc | 17.50m | -58.88m | 428.05m | 42.00 | -- | -- | -- | 24.46 | -2.11 | -2.11 | 0.6268 | -- | -- | -- | -- | 416,666.70 | -- | -39.77 | -- | -42.56 | -- | -- | -336.47 | -- | -- | -- | -- | -- | -- | -- | 60.07 | -- | -- | -- |
| Tectonic Therapeutic Inc | 0.00 | -74.15m | 431.86m | 60.00 | -- | 1.71 | -- | -- | -4.04 | -4.04 | 0.00 | 13.41 | 0.00 | -- | -- | 0.00 | -35.83 | -- | -37.77 | -- | -- | -- | -- | -- | -- | -- | 0.0015 | -- | -- | -- | -27.89 | -- | -- | -- |
| Immix Biopharma Inc | 0.00 | -23.56m | 436.00m | 18.00 | -- | 33.42 | -- | -- | -0.7742 | -0.7742 | 0.00 | 0.2502 | 0.00 | -- | -- | 0.00 | -104.21 | -108.46 | -169.47 | -146.18 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.11 | -- | 176.33 | -- |
Data as of Mar 03 2026. Currency figures normalised to Absci Corp's reporting currency: US Dollar USD
51.76%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 22.38m | 14.88% |
| ARK Investment Management LLCas of 31 Dec 2025 | 12.55m | 8.35% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 10.22m | 6.79% |
| Redmile Group LLCas of 31 Dec 2025 | 8.25m | 5.49% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 6.91m | 4.60% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 5.99m | 3.98% |
| Geode Capital Management LLCas of 31 Dec 2025 | 3.24m | 2.15% |
| Columbia Management Investment Advisers LLCas of 31 Dec 2025 | 3.20m | 2.13% |
| UBS Securities LLCas of 31 Dec 2025 | 2.69m | 1.79% |
| Columbia Wanger Asset Management LLCas of 30 Jun 2025 | 2.40m | 1.60% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
